Antisoma Articles
Novartis takes $120 million charge as it drops vadimezan development
11 November 2010
Antisoma plunges 72% after saying continuing late-stage NSCLC drug candidate development would be “futile”
29 March 2010
Showing 1-4 of 4 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
